📇 Rhumatologue · CRETEIL CEDEX · (94) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
10 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
9
9 articles ont été cités au moins 9fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
352
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
30
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
9
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Overview of the French Memory Centres healthcare pathway for patients with early Alzheimer disease
2024ArticleGériatrie et psychologie & neuropsychiatrie du vieillissement
Plasma Amyloid Beta Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment: The BALTAZAR Study
2022ArticleAlzheimer's & Dementia : the Journal of the Alzheimer's Association
What the COVID-19 pandemic entails for the management of patients with behavioral and psychological symptoms of dementia: experience in France
2020ArticleInternational Psychogeriatrics
Twenty‐year trends in patient referrals throughout the creation and development of a regional memory clinic network
2020ArticleAlzheimer's & Dementia: Translational Research & Clinical Interventions
Psychiatrists and neurologists in dementia care: Professionalism, practice, and perspectives
2020ArticleGeneral Hospital Psychiatry
Testing the therapeutic effects of transcranial direct current stimulation (tDCS) in semantic dementia: a double blind, sham controlled, randomized clinical trial
2019ArticleTrials
Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders
2018ArticleJournal of Alzheimer's Disease
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
2018ArticleAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP HM SITE HENRI MONDOR
51 AV MAL DE LATTRE DE TASSIGNY, 94010 CRETEIL CEDEX
HOPITAL LEOPOLD BELLAN
185 C R RAYMOND LOSSERAND, 75014 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Alzheimer's research & therapy · 2021
Abstract Background There is limited evidence on the characteristics and outcome of patients with dementia hospitalised for novel coronavirus infection (COVID-19). Method We conducted a prospective study in 2 gerontologic COVID units in Paris, France, from March 14, 2020, to May 7, 2020. Patients with dementia hospitalised for confirmed COVID-19 infection were systematically enrolled. A binary logistic regression analysis was performed to identify factors associated with mortality at 21 days. Results We included 125 patients. Median age was 86 (IQI 82–90); 59.4% were female. Most common causes of dementia were Alzheimer’s disease, mixed dementia and vascular dementia. 67.2% had ≥ 2 comorbidities; 40.2% lived in a long-term care facility. The most common symptoms at COVID-19 onset were confusion and delirium (82.4%), asthenia (76.8%) and fever (72.8%) before polypnea (51.2%) and desaturation (50.4%). Falls were frequent at the initial phase of the disease (35.2%). The fatality rate at 21 days was 22.4%. Chronic kidney disease and CRP at admission were independent factors of death. Persisting confusion, mood and behavioural disorders were observed in survivors (19.2%). Conclusion COVID-19 in demented individuals is associated with severe outcome in SARS-CoV-2 infection and is characterised by specific clinical features and complications, with confusion and delirium at the forefront. COVID-19 testing should be considered in front of any significant change from baseline.
Journal of Alzheimer's disease : JAD · 2016
Background: Few demographical data about primary progressive aphasia (PPA) are available, and most knowledge regarding PPA is based on tertiary centers’ results. Objective: Our aims were to describe demographical characteristics of the PPA population in a large sample of PPA patients from the network of French Alzheimer plan memory centers (Sample 1), and to describe the stratification of cerebrospinal fluid (CSF) biomarkers in two different samples of PPA patients (Samples 2 and 3). Methods: All registered PPA patients in the French Alzheimer’s disease (AD) databank (Sample 1: n = 2,035) and a subsample (Sample 2: n = 65) derived from a multicentric prospective cohort with CSF biomarker analysis were analyzed. A multicentric retrospective cohort from language expert tertiary centers (Sample 3: n = 97) with CSF biomarker analysis was added. Sample 3 was added to replicate the CSF results of the Sample 2 and to evaluate repartition of AD pathology in the three variant of PPA according to the latest classification. Results: Non-Fluent/Agrammatic, Logopenic, and Unclassifiable PPA patients (NF/A-Logo-Unclass PPA) were older and more frequent than Semantic PPA patients (2.2 versus 0.8/100,000 inhabitants; p < 0.00001). Male predominance occurred after the age of 80 ( p < 0.00001). A higher level of education was observed in the PPA population compared to a typical amnesic AD group. No demographical significant difference between PPA due to AD and not due to AD was observed. The Logopenic variant was most frequent with 85% of AD CSF biomarker profiles (35% in NF/A PPA; 20% in Semantic PPA). Conclusion: PPA occurs also in an elderly population, especially in male patients over 80. CSF biomarkers are useful to stratify PPA. The epidemiology of PPA should be further investigated to confirm gender and cognitive reserve role in PPA to better understand the factors and mechanisms leading to this language-predominant deficit during neurodegenerative diseases.
Nuclear medicine communications · 2012
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Geriatrie et psychologie neuropsychiatrie du vieillissement · 2024 · English Abstract
Ceccaldi M, Monteil-Hautin V, Chevrette A, Lebouvier T, et al.
Alzheimer's & dementia (New York, N. Y.) · 2020 · Journal Article
Chen Y, Lebouvier T, Skrobala E, Volpe-Gillot L, et al.
General hospital psychiatry · 2020 · Editorial
Brunn M, Diefenbacher A, Volpe-Gillot L
Journal of Alzheimer's disease : JAD · 2016 · Journal Article
Magnin E, Démonet JF, Wallon D, Dumurgier J, et al.
Nuclear medicine communications · 2012 · Journal Article
Farid K, Volpe-Gillot L, Petras S, Plou C, et al.
Presse medicale (Paris, France : 1983) · 2010 · Journal Article
Farid K, Volpe-Gillot L, Caillat-Vigneron N
Soins. Gerontologie · 2008 · Journal Article
Volpe-Gillot L, Bonté F
Journal of Alzheimer's disease : JAD · 2018 · Journal Article
Paquet C, Bouaziz-Amar E, Cognat E, Volpe-Gillot L, et al.
Alzheimer's research & therapy · 2021 · Journal Article
Vrillon A, Mhanna E, Aveneau C, Lebozec M, et al.
Trials · 2019 · Journal Article
Sanches C, Levy R, Benisty S, Volpe-Gillot L, et al.
Testing the therapeutic effects of transcranial direct current stimulation (tDCS) in semantic dementia: a double blind, sham controlled, randomized clinical trial
Abstract Background Semantic dementia is a neurodegenerative disease that primarily affects the left anterior temporal lobe, resulting in a gradual loss of conceptual knowledge. There is currently no validated treatment.
Testing the therapeutic effects of transcranial direct current stimulation (tDCS) in semantic dementia: a double blind, sham controlled, randomized clinical trial
Abstract Background Semantic dementia is a neurodegenerative disease that primarily affects the left anterior temporal lobe, resulting in a gradual loss of conceptual knowledge. There is currently no validated treatment.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).